AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Bristol-Myers Squibb and Adnexus in oncology collaboration.
(From AFX Europe (Focus))
LONDON (AFX) - Bristol-Myers Squibb Company and Adnexus Therapeutics announced a worldwide strategic alliance to discover, develop and commercialise Adnectin-based therapeutics for important oncology-related targets.
The companies aid the goal of the collaboration is to discover and develop biologic compounds specifically tuned to modulate oncology targets of high clinical impact.
Under the terms of the agreement, Bristol-Myers Squibb will provide some 30 mln usd over the next three years to Adnexus, consisting of upfront and guaranteed research payments.
Adnexus also is eligible to receive regulatory milestone …
-
- India's Biocon says unit signs research agreement with Bristol-Myers Squibb.
-
News wire article from: Europe Intelligence Wire
March 14, 2007
700+ words
-
- Bristol-Myers Squibb rating cut to A2 from A1 by Moody's; outlook stable.
-
News wire article from: Europe Intelligence Wire
September 13, 2006
700+ words
-
- Bristol-Myers Squibb offers to buy outstanding debt.
-
News wire article from: Europe Intelligence Wire
November 9, 2006
700+ words
-
- Bristol-Myers Squibb confirms Peter Dolan to leave as CEO effective immediately.
-
News wire article from: Europe Intelligence Wire
September 12, 2006
700+ words
-
- Bristol-Myers Squibb raises FY guidance despite narrowing Q3 earnings.
-
News wire article from: Europe Intelligence Wire
October 26, 2006
700+ words
